FA
PRAH

Friess Associates’s PRA Health Sciences, Inc. PRAH Stock Holding History

Friess Associates’s Portfolio PRAH Stock Details PRAH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-117,585
Closed -$13.1M – 152
2019
Q4 		$13.1M Sell
117,585
-4,150
-3% -$427K 0.91% 51
2019
Q3 		$12.1M Buy
121,735
+39,397
+48% +$3.91M 0.93% 54
2019
Q2 		$8.16M Buy
82,338
+2,436
+3% +$232K 0.6% 66
2019
Q1 		$8.81M Buy
79,902
+2,870
+4% +$300K 0.65% 59
2018
Q4 		$7.08M Hold
77,032
– – 0.61% 58
2018
Q3 		$8.49M Sell
77,032
-12
-0% -$1.25K 0.59% 59
2018
Q2 		$7.19M Hold
77,044
– – 0.57% 63
2018
Q1 		$6.39M Buy
77,044
+9,741
+14% +$866K 0.52% 71
2017
Q4 		$6.13M Buy
67,303
+1,654
+3% +$138K 0.51% 72
2017
Q3 		$5M Buy
65,649
+1,089
+2% +$82.3K 0.44% 71
2017
Q2 		$4.84M Buy
64,560
+6,260
+11% +$434K 0.44% 76
2017
Q1 		$3.8M Buy
+58,300
New +$3.43M 0.36% 75

Other funds holding PRAH

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NIPH
NN Investment Partners Holdings The Hague, Netherlands $18.6B AUM 18.31% 1-Year Est. Return
PG
Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Friess Associates's PRAH Position: Q1 2020 in Review

Friess Associates sold out of PRA Health Sciences, Inc. (PRAH) in Q1 2020, closing a stake of 117,585 shares — an estimated $13.1M sold.

Friess Associates first reported a position in PRAH in Q1 2017 and held it in 12 quarters. The position peaked at $13.1M in Q4 2019. 301 funds tracked by Wall St. Rank hold PRAH as of Q1 2020.

  • Friess Associates reported no remaining PRA Health Sciences, Inc. position as of Q1 2020 after selling out during the quarter.
  • Friess Associates sold 117,585 PRA Health Sciences, Inc. shares in Q1 2020, an estimated $13.1M.
  • Friess Associates first reported a position in PRA Health Sciences, Inc. in Q1 2017 and held it in 12 quarters.
  • Friess Associates's PRA Health Sciences, Inc. position peaked at $13.1M in Q4 2019.
  • 301 funds tracked by Wall St. Rank held PRA Health Sciences, Inc. as of Q1 2020.

Based on Friess Associates's 13F filing for Q1 2020, filed 15 May 2020.